RecruitingAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic Therapy

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Eligible age

Up to 22 yrs

Accepts

All genders

Locations

47 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Sponsor: PedAL BCU, LLC

You may qualify if…

✓ Patients must be less than 22 years of age at the time of study enrollment
✓ Patient must have one of the following at the time of study enrollment:
✓ Patient has known or suspected relapsed/refractory (including primary refractory) AML as defined in protocol
✓ This includes isolated myeloid sarcoma
✓ Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome (ML-DS)
✓ Patient has known or suspected relapsed ALL as defined in protocol that meets one of the following criteria:
✓ Second or greater B-ALL medullary relapse, excluding KMT2Ar
✓ Any first or greater B-ALL medullary relapse involving KMT2Ar